Many biostatisticians in pharma and biotech have relatively little awareness of, let alone influence over, the heavily statistical “pharmacometric” reasoning that goes into CTD Section 2.7.2 of an FDA regulatory submission, the “Summary of Clinical Pharmacology Studies”. This talk focuses on the value of increasing statistical influence in pharmacometrics and the path to get there.